Abbott Laboratories (NY:ABT)

Shares of healthcare product and device company Abbott Laboratories (NYSE:ABT) fell 8.3% in the afternoon session after the company reported fourth-quarter revenue that missed Wall Street's...

Topics Economy

These S&P500 stocks are moving in today's session ↗

January 22, 2026

Via Chartmill

Which S&P500 stocks have an unusual volume on Thursday? ↗

January 22, 2026

Via Chartmill

Why Abbott Laboratories (ABT) Shares Are Sliding Today

January 22, 2026

Abbott Laboratories (NYSE:ABT) Shares Slump on Q4 Revenue Miss and Nutrition Segment Weakness ↗

January 22, 2026

Via Chartmill

Abbott Laboratories (NYSE:ABT) Stands Out as a Dependable Dividend Stock for Income Investors ↗

January 17, 2026

Via Chartmill

Top S&P500 movers in Thursday's session ↗

January 22, 2026

Via Chartmill

Abbott (ABT) Q4 2025 Earnings Call Transcript ↗

January 22, 2026

Abbott (ABT) Q4 2025 Earnings Call Transcript

Abbott Shares Slump as Revenue Miss and Exact Sciences Acquisition Jitters Overshadow Earnings Beat

Topics Earnings World Trade

January 22, 2026

Abbott Laboratories (NYSE: ABT) saw its shares retreat by 5.8% in early trading on Thursday, January 22, 2026, following the release of its fourth-quarter financial results. Despite delivering an...

NVE (NVEC) Q3 2026 Earnings Call Transcript

Topics Earnings Economy

What's going on in today's session: S&P500 gap up and gap down stocks ↗

January 22, 2026

Via Chartmill

NVE (NVEC) Q3 2026 Earnings Call Transcript ↗

January 22, 2026

Healthcare product and device company Abbott Laboratories (NYSE:ABT) fell short of the markets revenue expectations in Q4 CY2025 as sales rose 4.4% year on year to $11.46 billion. Its non-GAAP profit...

Topics Earnings Supply Chain

Abbott Laboratories (NYSE:ABT) Misses Q4 CY2025 Revenue Estimates, Stock Drops

January 22, 2026

Their dividend streaks speak volumes.

Want Decades of Passive Income? 2 Stocks to Buy Right Now. ↗

January 22, 2026

Healthcare product and device company Abbott Laboratories (NYSE:ABT) will be announcing earnings results tomorrow before the bell. Here’s what to look for.

Topics Artificial Intelligence

Abbott Laboratories (ABT) Q4 Earnings Report Preview: What To Look For

January 21, 2026

Healthcare product and device company Abbott Laboratories (NYSE:ABT) will be reporting earnings this Thursday before market open. Here’s what to look for.

Topics Artificial Intelligence

What To Expect From Abbott Laboratories’s (ABT) Q4 Earnings

January 20, 2026

The global Mergers and Acquisitions (M&A) market staged a historic comeback in 2025, with total deal value reaching a staggering $5.1 trillion. This resurgence represents a 44% year-over-year increase,...

2 Healthcare Names That Could Get a Big Boost From Earnings ↗

January 20, 2026

Via MarketBeat

$5.1 Trillion Global Surge: CEO Confidence Ignites New Era of M&A Transformation

January 19, 2026

Income investors can rely on these stocks.

Topics Artificial Intelligence Economy Initial Public Offering

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever ↗

January 19, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and...

Topics Intellectual Property

1 Healthcare Stock to Consider Right Now and 2 We Find Risky

January 15, 2026

The Great Diagnostic Consolidation: How a $25.7 Billion Mega-Deal Ignited a 150% Surge in Healthcare M&A

Topics Stocks

January 14, 2026

As 2026 begins, the healthcare sector is undergoing its most profound transformation in decades. Driven by a relentless push toward "precision medicine" and the industrialization of artificial...

For the past two years, the U.S. healthcare sector has been the forgotten stepchild of the equity markets. As the S&P 500 (SPX) surged on the back of an artificial intelligence gold rush and a...

Topics Artificial Intelligence

The Great Recalibration: Why 2026 Could Be Healthcare’s Year to Rebound

January 13, 2026

GRAIL Surges as Canaccord Genuity Sets Ambitious $105 Price Target Following Robust 2025 Growth

Topics Artificial Intelligence Economy Intellectual Property

January 13, 2026

In a resounding vote of confidence for the future of multi-cancer early detection (MCED), Canaccord Genuity reiterated its "Buy" rating for GRAIL (Nasdaq: GRAL) on Tuesday, January 13, 2026, setting an...

On January 12, 2026, the diagnostic sector witnessed a seismic shift as shares of Biodesix (Nasdaq: BDSX) surged more than 40% in early trading, following the release of preliminary full-year 2025...

Biodesix Shares Rocket 42% on Record FY2025 Results and Path to Profitability

January 12, 2026

It's important to diversify and focus on the long term.

Topics Artificial Intelligence Death

Where to Invest $10,000 at the Start of This New Year ↗

January 12, 2026

Date: January 9, 2026 Introduction As the global healthcare landscape undergoes a seismic shift toward personalized medicine and AI-integrated care, Medtronic plc (NYSE: MDT) stands at a critical...

Topics Artificial Intelligence

Medtronic (MDT) Deep-Dive: Can the MedTech Giant Outpace the Market in 2026?

January 09, 2026

Via PredictStreet

Topics Artificial Intelligence Economy Product Recall

1 S&P 500 Stock to Consider Right Now and 2 We Turn Down

January 07, 2026

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some...

They can help you weather the storm.

Topics Stocks

2 Healthcare Stocks to Buy in a Bear Market ↗

January 03, 2026

As of today, January 1, 2026, Abbott Laboratories (NYSE: ABT) stands as one of the most resilient and strategically diversified giants in the global healthcare landscape. While the broader market has...

Topics Economy

The Evolution of a Healthcare Giant: Abbott Laboratories (ABT) 2026 Stock Feature

January 01, 2026

Via PredictStreet

Topics Economy Lawsuit World Trade

Abbott Laboratories (ABT): Buy, Sell, or Hold Post Q3 Earnings?

December 31, 2025

Over the past six months, Abbott Laboratories’s shares (currently trading at $125.45) have posted a disappointing 7.9% loss, well below the S&P 500’s 11.2% gain. This may have investors wondering how...

This basket of 64 medical device stocks could raise its dividend for decades.

Topics Stocks Supply Chain

Is Fidelity Medical Equipment the Ultimate "Forever Fund" for Health Care Investors? ↗

December 24, 2025